Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies

Mayo Clinic Proceedings

Volumn 72, Issue 11, 1997, Pages 1080-1089

  Erickson, Bradley J ^a   Noseworthy, John H ^a,b  

^a Department of Diagnostic Radiology ^*  (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYCLOSPORIN; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

EID: 0030770981     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.11.1080     Document Type: Conference Paper

References (96)

1. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC (Canadian Cooperative MS Study Group). Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-975
2. Noseworthy JH. Clinical scoring methods for multiple sclerosis. AnnNeurol 1994;36(Suppl):S80-S85
3. Johnson MA, Li DK, Bryant DJ, Payne JA. Magnetic resonance imaging: serial observations in multiple sclerosis. AJNR Am J Neuroradiol 1984;5:495-499
4. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988;169:117-122
5. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180:467-474
6. Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C, et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990;40:591-595
7. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. AnnNeurol 1991;29:548555
8. Ormerod IE, Miller DH, McDonald WI, du Boulay EP, Rudge P, Kendall BE, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain 1987;! 10:1579-1616
9. Wiebe S, Lee DH, Karlik SJ, Hopkins M, Vandervoort MK, Wong CJ, et al. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. AnnNeurol 1992;32:643-650
10. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993 ;43:1401 -1406
11. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993:116:1077-1094
12. Kidd D, Thompson AJ. Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-1072
13. Filippi M, Campi A, Mammi S, Martinelli V, Locatelli T, Scotti G, et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;58:31-37
14. Koopmans RA, Li DK, Grochowski E, Cutler PJ, Paty DW. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. AnnNeurol 1989;25:74-81
15. Koopmans RA, Li DK, Oger JJ, Kastrukoff LF, Jardine C, Costley L, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. AnnNeurol 1989;26:248-256
16. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990:300:631-634
17. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;! 19:2009-2019
18. Losseff N A, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;! 19:701-708
19. van Walderveen MAA, Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin STFM, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on shortTR/short-TE (Tl-weighted) spin-echo images. Neurology 1995; 45:1684-1690
20. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994;4:141-145
21. Filippi M, Yousry T, Campi A, KandzioraC, Colombo B, Voltz R, et al. Comparison of triple dose versus standard dose gadoliniumDTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-384
22. Filippi M, Capra R, Campi A, Colombo B, Prandini F, Marciano N, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526-530
23. Filippi M, Campi A, Martinelli V, Colombo B, Yousry T, Canal N, et al. Comparison of triple dose versus standard dose gadoliniumDTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:540-544
24. Gawne-Cain ML, Webb S, Tofts P, Miller DH. Lesion volume measurement in multiple sclerosis: how important is accurate repositioning? J Magn Reson Imaging 1996;6:705-713
25. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 1986;3:823-833
26. Sheldon PE, Rothschild PA, Kramer DM, Hale JD, Kaufman L. Impact of section doubling on lesion contrast. Radiology 1991; 180:123-125
27. Rovaris M, Gawne-Cain ML, Wang L, Miller DH. A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. Neuroradiology 1997;39:161-165
28. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sei 1988;15:266-272
29. Pannizzo F, Stallmeyer MJB, Friedman J, Jennis RJ, Zabriskie J, Plank C, et al. Quantitative MRI studies for assessment of multiple sclerosis. Magn Reson Med 1992;24:90-99
30. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
31. Jackson EF, Narayana PA, Wolinsky JS, Doyle TJ. Accuracy and reproducibility in volumetric analysis of multiple sclerosis lesions. J Comput Assist Tomogr 1993 ; 17:200-205
32. Mitchell JR, Karlik SJ, Lee DH, Fenster A. Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brain. J Magn Reson Imaging 1994;4:197208
33. Erickson BJ, Avula RTV. An automatic classification of tissues and multiple sclerosis lesions in magnetic resonance images of the brain [submitted for publication]
34. Hajnal JV, Bryant DJ, Kasuboski L, Pattany PM, De Coene B, Lewis PD, et al. Use of fluid attenuated inversion recovery (FLAIR) pulse sequences in MRI of the brain. J Comput Assist Tomogr 1992; 16:841-844
35. White SJ, Hajnal JV, Young IR, Bydder GM. Use of fluid-attenuated inversion-recovery pulse sequences for imaging the spinal cord. Magn Reson Med 1992;28:153-162
36. De Coene B, Hajnal JV, Pennock JM, Bydder GM. MRI of the brain stem using fluid attenuated inversion recovery pulse sequences. Neuroradiology 1993;35:327-331
37. Rydberg JN, Hammond CA, Grimm RC, Erickson BJ, Jack CR Jr, Huston J III, et al. Initial clinical experience in MR imaging of the brain with a fast fluid-attenuated inversion-recovery pulse sequence. Radiology 1994;193:173-180
38. Haughton VM, Yetkin FZ, Rao SM, Rimm AA, Fischer ME, Papke RA, et al. Quantitative MR in the diagnosis of multiple sclerosis. Magn Reson Med 1992;26:71-78
39. Zamaroczy D, Schluesener HJ, Jolesz FA, Sobel RA, Colucci VM, Weiner HL, et al. Differentiation of experimental white matter lesions using multiparametric magnetic resonance measurements. Invest Radiol 1991;26:317-324
40. Larsson HBW, Frederiksen J, Kjaer L, Henriksen O, Olesen J. In vivo determination of Tl and T2 in the brain of patients with severe but stable multiple sclerosis. Magn Reson Med 1988;7:43-55
41. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989; 10:135-144
42. Eng J, Ceckler TL, Balaban RS. Quantitative 1H magnetization transfer imaging in vivo. Magn Reson Med 1991;17:304-314
43. Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Scarano F, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging [published erratum appears in Radiology 1992;183:878]. Radiology 1992;182:483-491
44. Hiehle JF Jr, Lenkinski RE, Grossman RI, Dousset V, Ramer KN, Schnall MD, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med 1994;32:285-293
45. Tomiak MM, Rosenblum JD, Prager JM, Metz CE. Magnetization transfer: a potential method to determine the age of multiple sclerosis lesions. AJNR Am J Neuroradiol 1994; 15:1569-1574
46. Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995;45:478-482
47. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632-636
48. MehtaRC, PikeGB,EnzmannDR. Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer. AJNR Am J Neuroradiol 1995;16:1771-1778
49. Loevner LA, Grossman RI, McGowan JC, Ramer KN, Cohen JA. Characterization of multiple sclerosis plaques in T l-weighted MR and quantitative magnetization transfer. AJNR Am J Neuroradiol 1995;16:1473-1479
50. Hiehle JF Jr, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995;16:69-77
51. Larsson HBW, Christiansen P, Jensen M, Frederiksen J, Heltberg A, Olesen J, et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 1991;22:2331
52. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;! 19:715-722
53. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neuol 1994;36:76-82
54. Sappey-Marinier D. High-resolution NMR spectroscopy of cerebral white matter in multiple sclerosis. Magn Reson Med 1990;15:229239
55. Sakuma H, Nomura Y, Takeda K, Tagami T, Nakagawa T, Tamagawa Y, et al. Adult and neonatal human brain: diffusional anisotropy and myelination with diffusion-weighted MR imaging. Radiology 1991; 180:229-233
56. Hajnal JV, Doran M, Hall AS, Collins AG, Oatridge A, Pennock JM, et al. MR imaging of anisotropically restricted diffusion of water in the nervous system: technical, anatomic, and pathologic considerations. J Comput Assist Tomogr 1991;15:1-18
57. Christiansen P, Gideon P, Thomsen C, Stubgaard M, Henriksen O, Larsson HB. Increased water self-diffusion in chronic plaques and in apparently normal white matter in patients with multiple sclerosis. Acta Neurol Scand 1993 ; 87:195-199
58. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33: 1444-1452
59. Kappos L, Stadt D, Ratzka M, Keil W, Schneiderbanger-Grygier S, Heitzer T, et al. Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology 1988;30:299-302
60. Bastianello S, Pozzilli C, D'Andréa F, Millefiorini E, Trojano M, Morino S, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sei 1994;21:266-270
61. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480489
62. Stone LA, Smith ME, Albert PS, Bash CN, Maloni H, Frank JA, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995 ;45:1122-1126
63. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis: a critical analysis. Mult Scler 1995; 1:37-47
64. Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am JRoentgenol 1992;159:1041-1047
65. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986; 161:721-725
66. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49
67. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63
68. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36(Suppl):S86-S90
69. IFNB Multiple Sclerosis Study Group. Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
70. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
71. Khoury SJ, Guttman CR, Orav EJ, Hohol MJ, Ahn SS, Hsu L, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124
72. Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. NEnglJMed 1982;306:1529-1533
73. Ormerod IE, Johnson G, MacManus D, du Boulay EP, McDonald WI. Relaxation times of apparently normal cerebral white matter in multiple sclerosis. Acta Radiol Suppl 1986;369:382-384
74. Miller DH, Johnson G, Tofts PS, MacManus D, McDonald WI. Precise relaxation time measurements of normal-appearing white matter in inflammatory central nervous system disease. Magn Reson Med 1989; 11:331-336
75. Armspach JP, Gounot D, Rumbach L, Chambron J. In vivo determination of multiexponential T2 relaxation in the brain of patients with multiple sclerosis. Magn Reson Imaging 1991;9:107-113
76. Narayana PA, Wolinsky JS, Jackson EF, McCarthy M. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging 1992;2:263-270
77. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40:1764-1769
78. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;! 17:49-58
79. Kastrukoff LF, Oger JJ, Hashimoto SA, Sacks SL, Li DK, Palmer MR, et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990;40:479-486
80. Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990:27:591-605
81. Koopmans RA, Li DK, Zhao GJ, Redekop WK, Paty DW. MRI assessment of cyclosporine therapy of MS in a multi-center trial [abstract]. Neurology 1992;42(Suppl 3):210
82. Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multicenter study. Ann Neurol 1988;23:56-63
83. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413
84. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13
85. Lindsey JW, Hodgkinson S, Mehta R, Siegel RC, Mitchell DJ, Lim M, et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994;44:413-419
86. Moreau T, Thorpe J, Miller D, Moseley I, Haie G, Waldmann H, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994:344:486]. Lancet 1994;344:298-301
87. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995:37:113-119
88. Wiles CM, Omar L, Swan AV, Sawle G, Frankel J. Grunewald R, et al. Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;57:154-163
89. Cook SD, Bansil S, Boos J, Devereux C, Haffty B, Goldstein J, et al. Total lymphoid irradiation (TLI) and low-dose prednisone (LDP) in progressive multiple sclerosis (PMS) [abstract]. Neurology 1995;45(Suppl4):A417
90. Cohen JA, Grossman RI, Udupa JK, Samarasekera S, Miki Y, Polansky M, et al. Assessment of the efficacy of Copolymer-1 in the treatment of multiple sclerosis by quantitative MRI [abstract]. Neurology 1995;45(Suppl4):A418
91. Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996;47:895-900
92. Karussis DM, Meiner Z, Lehmann D, Gomori JM, Schwarz A, Linde A, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996:47:341-346
93. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al (Multiple Sclerosis Collaborative Research Group [MSCRG]). Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996:39:285-294
94. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al (Copolymer 1 Multiple Sclerosis Study Group). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995:45:1268-1276
95. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1 b: experience during the first three years. Neurology 1996;47:889-894
96. Hunter SF, Weinshenker BG, Carter JL, Noseworthy JH. Rational clinical immunotherapy for multiple sclerosis. Mayo Clin Proc 1997:72:765-780